

Education Evidence Experience

ELEVATE

RAISING EXPECTATIONS:
ADVANCING SCIENCE IN HR+/HER2- mBC

DAY 1

FRIDAY 12 MAY

13:00	Welcome to Berlin
13:10	Raising the bar in HR+/HER2- mBC management for 2017
Current management in HR+/HER2- mBC EDUCATION	
13:15	Are we aligned? Expectations and reality in the management of HR+/HER2- mBC
13:45	Perspectives from the panel: time to re-evaluate our expectations?
CDK4/6 inhibitors: advancing science in the HR+/HER2- mBC field EVIDENCE	
14:15	Advancing science: from cell cycle to the clinic
15:00	Q&A
15:15	Coffee
Clinical challenges EXPERIENCE	
15:45	Clinical challenges: experience across different patient populations
16:05	Clinical challenges workshop: your perspectives on case studies
18:00	Day 1 close and dinner

DAY 2

SATURDAY 13 MAY

09:00	Welcome to Day 2 of ELEVATE
Raising expectations in HR+/HER2- mBC: the patient's view EDUCATION	
09:10	The patient perspective on healthcare for mBC
Incorporating CDK4/6 inhibitors into clinical practice: therapy management considerations EVIDENCE	
09:40	What to expect & QoL considerations
10:20	Practical viewpoint
10:40	Q&A
11:00	Coffee
Evidence in context EXPERIENCE	
11:15	CDK4/6 inhibitors in clinical practice: a view from the US
Raising expectations in HR+/HER2- mBC: how might new treatment options impact? EDUCATION	
12:00	Using the latest evidence to advance our management of HR+/HER2- mBC
Elevating breast cancer management in 2017	
12:20	Questions from the audience
12:50	Close
13:00	Lunch and departures

Education Evidence Experience

ELEVATE

RAISING EXPECTATIONS:
ADVANCING SCIENCE IN HR+/HER2- mBC

12-13 May 2017
Berlin Congress Center, Germany



ELEVATE

RAISING EXPECTATIONS:
ADVANCING SCIENCE IN HR+/HER2- mBC

We are delighted to invite you to attend the **ELEVATE** meeting on **12–13 May, 2017** at the **Berlin Congress Center in Berlin, Germany**. This Pfizer-sponsored educational initiative will provide an interactive forum for specialists in metastatic breast cancer (mBC) to discuss the latest evidence and share clinical experience in the treatment of HR+/HER2- disease.

Aiming to raise expectations and advance the science of mBC, the meeting will be led by international experts who will give their insights on the latest scientific developments in the changing landscape of HR+/HER2- disease, with a focus on the pioneering CDK4/6 inhibitors.

The distinguished faculty will:

- analyse the impact of CDK4/6 inhibitors on treatment strategies in clinical practice
- discuss key aspects of therapy management
- explore the patient's perspective on healthcare for mBC.

Delegates will have the opportunity to share experience and discuss management strategies through workshop-based case studies. The meeting will also include discussions evaluating progress towards addressing unmet needs in mBC.

We look forward to welcoming you to what promises to be a stimulating and informative meeting.

Best regards

The Pfizer Oncology Breast Cancer Team

CO-CHAIRS

Sibylle Loibl

German Breast Group, Frankfurt, Germany

Nick Turner

Institute of Cancer Research, London, UK

FACULTY

Fabrice André

Institut Gustave Roussy, Villejuif, France

Adam Brufsky

University of Pittsburgh Department of Medicine, Pittsburgh, USA

Johannes Ettl

Technical University of Munich, Munich, Germany

Giuseppe Curigliano

European Institute of Oncology, Milan, Italy

Eva Schumacher-Wulf

MammaMia! – The Breast Cancer Magazine, Kronberg, Germany

